Blood markers and breast cancer treatment results
Part of Cancer, Skin clinical trials.
This study looks at how age-related changes in your blood might affect how well your breast cancer treatment works. It includes people with hormone receptor-positive, HER2-negative breast cancer that has not spread to distant organs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You are female.
- You have breast cancer that shows receptors for estrogen or progesterone (ER+ or PR+).
- Your breast cancer is not HER2-positive (HER2-).
- Your cancer has not spread to other parts of the body (no distant metastasis).
- You do not have a history of other cancers, except for certain skin cancers or cervical cancer that was treated and gone for more than 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study examines tiny particles in your blood from breast cancer cells to better predict which treatments will work best for you. Researchers will collect blood samples and a small tissue sample to understand your cancer's characteristics and help doctors choose more effective therapy.
This study looks at substances in your blood (metabolites) to see if they are linked to breast cancer risk, how well treatment works, and long-term outcomes. It has three groups: women without breast cancer, newly diagnosed patients getting standard therapy, and those who have finished treatment.
This trial uses a special blood test to track cancer signals (called ctDNA) during and after treatment for early breast cancer. It aims to see whether monitoring these signals can help guide follow-up and treatment decisions.
This trial looks at differences between younger and older breast cancer patients to better understand the disease. If you had breast cancer between the ages of 18 and 75 and were treated in a Chinese hospital from 2000 to 2024, you might be able to help.
This study looks at how your immune system changes while you receive standard breast cancer treatments. The researchers measure immune-related signals during your treatment to better understand what may be happening in triple-negative or certain hormone-receptor breast cancers.
This study looks at breast cancer samples taken by biopsy to see how tissue “molecular markers” relate to how you respond to therapy and how the cancer behaves. It may help researchers better match future treatments to the biology of your tumor.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.